A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.
Early Hum Dev. 1996 Jul 19;45(3):203-14. PMID: 2565585
This study reports the results of a trial of essential fatty acid (EFA) supplementation in psychiatric patients (predominantly schizophrenics) with movement disorders. Evidence of EFA deficiency in these patients was observed. The antidyskinetic effect of EFA supplementation was marginally significant but not clinically important. However, active treatment produced highly significant improvements in total psychopathology scores and schizophrenia subscale scores, and a significant improvement in memory.